HEPATOLOGY INFORMATION CENTER
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
Women less likely to be treated than men; treatment visit, medication tied to improved 1-year outcomes.
Increased-risk donors significantly more likely to have positive HBV, HCV screening results.
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
There is a lack of consensus among experts and professional organizations whether HCV screening in pregnant women should be risk based or universal.